CSL Behring shuts down California cell and gene therapy R&D site amid group pivot

In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutting down its U.S. R&D hub for cell and gene therapy in Pasadena, California, Fierce Biotech has learned.